Last reviewed · How we verify
ARQ-154
ARQ-154 is a topical Janus kinase (JAK) inhibitor.
ARQ-154 is a topical Janus kinase (JAK) inhibitor. Used for Moderate to severe atopic dermatitis, Moderate to severe psoriasis.
At a glance
| Generic name | ARQ-154 |
|---|---|
| Sponsor | Arcutis Biotherapeutics, Inc. |
| Drug class | JAK inhibitor |
| Target | JAK |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the activity of JAK enzymes, which play a key role in the inflammatory response. By blocking these enzymes, ARQ-154 reduces inflammation and modulates the immune response. This mechanism of action is thought to be beneficial for the treatment of various skin conditions.
Approved indications
- Moderate to severe atopic dermatitis
- Moderate to severe psoriasis
Common side effects
- Application site reactions
- Headache
- Nausea
Key clinical trials
- Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis (PHASE1)
- Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (PHASE3)
- Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis (PHASE2)
- Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) (PHASE3)
- Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis (PHASE2)
- Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |